Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.91 -0.21%
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $1.54, $0.30 better than the analyst estimate of $1.24. Revenue for the quarter came in at $326 million versus the consensus estimate of $286.01 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $6.00-$6.40, versus the consensus of $5.40. Halozyme Therapeutics sees FY2025 revenue of $1.27-1.35 billion, versus the consensus of $1.25 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- Citi reiterates neutral rating on Okta amid data leak concerns
- Oil States International (OIS) PT Lowered to $11 at Raymond James
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
